Cancer Chemotherapy and Pharmacology · 2014 · 30 citations · 15 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyDrug InteractionsPharmacodynamicsDrug DispositionDrug Interactions In ChemotherapyDrug-drug Interactions In MetabolismPharmacokinetic Drug InteractionsPharmacokinetics In Children With CancerPharmacokinetics Of Anticancer DrugsArea Under The Plasma Concentration-time CurveDrug-drug Interactions Affecting MetabolismLenalidomide TherapyPlasma Concentration - Time ProfilePlasma Concentration-time AnalysisQuinidine TherapyRenal Drug ExcretionRenal Drug Interactions
PURPOSE: Lenalidomide, a weak substrate of P-glycoprotein (P-gp) in vitro, is an oral anticancer drug eliminated predominantly via renal excretion as unchanged compound. The role of P-gp in lenalidomide disposition and the associated clinical relevance were evaluated. METHODS: Two phase I, crossover studies were conducted in healthy volunteers. In Study 1, subjects received lenalidomide (10 mg × 7 days) alone or with the P-gp substrate digoxin (0.5 mg on Day 5). In Study 2, subjects received lenalidomide (a single 25 mg dose) alone, the P-gp inhibitor quinidine (300-600 mg twice-daily × 5 days) plus lenalidomide (on Day 4), the P-gp inhibitor/substrate temsirolimus (a single 25 mg dose) alone, or lenalidomide plus temsirolimus. Pharmacokinetic and safety data were collected for lenalidomide and the co-administrated drugs. RESULTS: There were no significant changes in the maximum concentration (C max) and area under the plasma concentration-time curve (AUC) of lenalidomide when co-administered with quinidine, digoxin, or temsirolimus. Neither the rate nor the capacity of lenalidomide renal excretion was affected by quinidine or temsirolimus, in addition lenalidomide absorption rate and bioavailability remained unchanged. Furthermore, lenalidomide had no significant effect on blood C max and AUC of temsirolimus and its active metabolite sirolimus (also a P-gp inhibitor/substrate). The C max of digoxin was slightly higher (+14 %) when administered with lenalidomide versus placebo. There were no other changes in digoxin pharmacokinetics upon co-administration with lenalidomide. No remarkable safety findings were observed. CONCLUSIONS: There are no clinically significant pharmacokinetic interactions between lenalidomide and substrates or inhibitors of P-gp.
15
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Susan P.C. Cole, Gabu Bhardwaj, James H. Gerlach et al. · Science · 1992 · 3.1K citations
Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion
Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations
Medicine, Hematology, Pharmacology +17
Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Donna M. Weber, Christine Chen, Rubén Niesvizky et al. · New England Journal of Medicine · 2007 · 1.2K citations · Full text
Pierre Fenaux, Aristoteles Giagounidis, Dominik Selleslag et al. · Blood · 2011 · 480 citations · Full text
Medicine, Hematology, Pharmacology +14